AstraZeneca's bid for approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has been acknowledged for review by the US Food and Drug Administration (FDA). If greenlit, this vaccine would mark a significant stride as the foremost self-administered flu vaccine accessible to eligible patients or administered by caregivers, widening the spectrum of choices for influenza immunization.

Supported by a usability study, the application confirms that individuals over 18 years of age could competently self-administer or administer FluMist to eligible patients aged 2-49 years when provided with usage instructions, sans additional guidance. FluMist, administered via nasal spray, boasts extensive data showcasing comparable efficacy and safety relative to other flu vaccines.

The Prescription Drug User Fee Act (PDUFA) date, marking the FDA's regulatory verdict, is slated for the first quarter of 2024. Pending approval, FluMist is expected to be procurable for self-administration in the US during the 2024/2025 flu season.

Ravi Jhaveri, MD, Division Head, Infectious Disease at Northwestern University School of Medicine, underscores the significance of a self-administered option for FluMist Quadrivalent in enhancing accessibility, potentially bolstering vaccination rates.

Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, reflects on FluMist Quadrivalent's longstanding role as a public health tool and envisions its potential to revolutionize flu vaccination by becoming the premier self-administered flu vaccine.

Influenza, a contagious respiratory illness, poses substantial risks to vulnerable groups. FluMist Quadrivalent, a quadrivalent live attenuated influenza vaccine (LAIV), presents an intranasal spray option for influenza prevention, recommended by the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP).